Showing results (191-200 of 243) with videos related to
Sort By:
Pageof 25
The New England Journal of Medicine|October 17, 2025
Survival with Osimertinib plus Chemotherapy in <i>EGFR</i>-Mutated Advanced NSCLCPasi A Jänne, David Planchard, Kunihiko Kobayashi, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 20, 2019
Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint InhibitorsLizza E L Hendriks, Clemence Henon, Edouard Auclin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 22, 2017
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension ComponentJames Chih-Hsin Yang, Myung-Ju Ahn, Dong-Wan Kim, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2026
Role of ctDNA Tumor Fraction in Selecting Immunotherapy Based Regimens in Advanced Non-small Cell Lung CancerFilippo G Dall'Olio, Wael Zrafi, Damien Vasseur, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 5, 2020
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based ChemotherapyRoberto Ferrara, Marie Naigeon, Edouard Auclin, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 1, 2025
Final Analysis Results and Patient-Reported Outcomes From DESTINY-Lung02-A Dose-Blinded, Randomized, Phase 2 Study of Trastuzumab Deruxtecan in Patients With HER2-Mutant Metastatic NSCLCPasi A Jänne, Yasushi Goto, Toshio Kubo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 6, 2025
Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 StudyJacob Sands, Myung-Ju Ahn, Aaron Lisberg, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 25, 2019
Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 StudiesHyun Cheol Chung, Sarina A Piha-Paul, Jose Lopez-Martin, et al.The New England Journal of Medicine|November 22, 2019
Overall Survival with Osimertinib in Untreated, <i>EGFR</i>-Mutated Advanced NSCLCSuresh S Ramalingam, Johan Vansteenkiste, David Planchard, et al.JTO Clinical and Research Reports|June 29, 2026
Telisotuzumab Vedotin Monotherapy in Patients With Previously Treated c-Met Protein Overexpressing, Nonsquamous, <i>EGFR</i> Wild-type Advanced NSCLC: Updated Analysis of the LUMINOSITY TrialNicolas Girard, Jonathan Goldman, Shun Lu, et al.Pageof 25